Resolve: stage-specific TREM2 agonist-to-antagonist switching by amyloid/tau biomarkers

Bounty tier: $750K staged in-vivo validation. The challenge tests a precision-medicine rule, not simple TREM2 modulation. Falsifiable prediction: in an amyloid-to-tau progression model, TREM2 agonism initiated during amyloid-positive/tau-low stage will reduce plaque burden by >=25% and improve microglial phagocytic markers, while the same agonism in tau-high stage will increase inflammatory SPP1/C1q module scores by >=30% and fail cognition endpoints. Switching to partial TREM2 antagonism at tau-high biomarker threshold should reduce inflammatory module scores >=25% without rebound plaque increase >10%.